Business Wire

INTERSOLAR-EUROPE

22.4.2022 09:41:05 CEST | Business Wire | Press release

Share
INTERSOLAR EUROPE 2022: FOCUS ON INTELLIGENT DUAL USE OF AREAS

At the Intersolar Europe exhibition, established and new players in the energy sector exchange information about new developments and trends, experience innovations and exploit business potential. The focus of the world’s leading exhibition for the solar industry is, among other things, the dual use of areas in agriculture, on bodies of water and in buildings. Intersolar Europe will be held at Messe München from May 11 to 13.

Photovoltaic (PV) production is booming in Germany and throughout Europe: almost 26 gigawatts (GW) of PV installations were connected to the grid in the EU in 2021 – a record growth of 34%. As in the previous year, Germany was the largest PV market in the EU with an addition of 5.3 GW. The European inter-trade organization, SolarPower Europe, expects installed solar power capacity to double to more than 326 GW by 2025.

At Intersolar Europe 2022, companies will present innovations and products developed for the world of new energies. Some examples include Agri-photovoltaics and Floating PV. The efficient dual use of areas for agriculture and solar power generation is developing dynamically: in 2020, plants for the generation of more than 14 GW had already been installed worldwide, according to the Fraunhofer Institute for Solar Energy Systems (ISE). Floating PV is now considered the third pillar of the global solar market. An estimated 400 plants with a total capacity of more than 3 GW are already in operation in over 40 countries. At Intersolar Europe 2022, these rapid developments will be prominent, with a large number of exhibitors presenting innovative products and solutions from the Agri-PV and Floating PV sectors.

Building-integrated PV (BIPV) is another key topic at Intersolar Europe 2022. With a view to the German market, this is where the greatest potential can be found for reducing the CO2 footprint of buildings, using space efficiently and strengthening sustainable development.

Intersolar Europe forms part of The smarter E Europe. From May 11 to 13, 2022, it will present cross-industry and cross-sector solutions for the energy transition and security of supply in Europe at Messe München. 1,450 exhibitors will showcase products, solutions and business models across 132,000 square meters in twelve exhibition halls.

Topics such as Agri-PV, Floating PV and BIPV will also be addressed at the Intersolar Europe Conference on May 10 and 11, 2022 at the International Congress Center Munich (ICM). Participants will learn all about the markets, technologies and financing of PV projects. One area under the spotlight will be large-scale PV power plants and systems, especially with regard to Agri-PV and floating PV. On May 10 at 6 p.m., innovators and experts will be honored with the Intersolar AWARD at the ICM (Hall 1).

https://www.intersolar.de/home?lang=en

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye